This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignees: Novartis Ag, Novartis Pharma Ag. Active years: 2018-2025.
Location History:
- Basel, CH (2018)
- Buckinghamshire, GB (2021)
Company Filing History:
Years Active: 2018-2025
Title: Innovations by James Warburton in Ocular Treatments
Introduction
James Warburton is an accomplished inventor based in Buckinghamshire, GB. He has made significant contributions to the field of ocular treatments, holding a total of 3 patents. His work focuses on methods that aim to alleviate the treatment burden for patients suffering from intraocular neovascular disorders.
Latest Patents
Warburton's latest patents include innovative methods for treating age-related macular degeneration. One of his notable inventions provides a method for reducing the treatment burden for patients by administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks. Another significant patent involves methods for treating ocular diseases with brolucizumab, which similarly aims to reduce the treatment burden for patients with intraocular neovascular disorders.
Career Highlights
Throughout his career, Warburton has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Novartis Pharma AG. His experience in these organizations has allowed him to develop and refine his innovative approaches to ocular treatments.
Collaborations
Some of his notable coworkers include Peter Sallstig and Andreas Weichselberger. Their collaboration has likely contributed to the advancements in the field of ocular health.
Conclusion
James Warburton's contributions to ocular treatments through his patents demonstrate his commitment to improving patient care. His innovative methods are paving the way for more effective treatment options in the field of ophthalmology.